These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

996 related items for PubMed ID: 10092816

  • 1. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 3. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S.
    Cancer Res; 1996 Oct 01; 56(19):4338-42. PubMed ID: 8813119
    [Abstract] [Full Text] [Related]

  • 4. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H, Shu S.
    J Immunol; 1998 Apr 01; 160(7):3444-52. PubMed ID: 9531305
    [Abstract] [Full Text] [Related]

  • 5. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.
    Cancer Res; 2003 May 15; 63(10):2546-52. PubMed ID: 12750278
    [Abstract] [Full Text] [Related]

  • 6. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H, Chang AE, Shu SY.
    Cancer Res; 1992 Mar 01; 52(5):1129-36. PubMed ID: 1531321
    [Abstract] [Full Text] [Related]

  • 7. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM, Urba WJ, Fox BA.
    J Immunol; 1998 Sep 15; 161(6):3033-41. PubMed ID: 9743368
    [Abstract] [Full Text] [Related]

  • 8. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE.
    Cancer Gene Ther; 1996 Oct 15; 3(1):39-47. PubMed ID: 8785710
    [Abstract] [Full Text] [Related]

  • 10. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE.
    Cancer Gene Ther; 1997 Oct 15; 4(3):157-66. PubMed ID: 9171934
    [Abstract] [Full Text] [Related]

  • 11. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 12. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1993 Sep 15; 53(18):4315-21. PubMed ID: 8364926
    [Abstract] [Full Text] [Related]

  • 13. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 15; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 14. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression.
    Kjaergaard J, Shu S.
    J Immunol; 1999 Jul 15; 163(2):751-9. PubMed ID: 10395667
    [Abstract] [Full Text] [Related]

  • 15. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S.
    Cancer Res; 2001 Mar 01; 61(5):2031-7. PubMed ID: 11280763
    [Abstract] [Full Text] [Related]

  • 16. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 01; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y, Wang H, Zhao J, Ma J, Wei L, Wu S, Xie T, Shen F, Trojan J, Habib N, Anthony DD, Wu M, Guo Y.
    Cancer Gene Ther; 2000 Mar 01; 7(3):456-65. PubMed ID: 10766352
    [Abstract] [Full Text] [Related]

  • 18. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 19. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 20. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
    Sussman JJ, Parihar R, Winstead K, Finkelman FD.
    Cancer Res; 2004 Dec 15; 64(24):9124-30. PubMed ID: 15604282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.